BRIEF-Ocuphire Pharma announces acquisition of Opus Genetics

Reuters10-23

Oct 22 (Reuters) - Ocuphire Pharma Inc :

* OCUPHIRE PHARMA ANNOUNCES ACQUISITION OF OPUS GENETICS

* OCUPHIRE PHARMA INC - PROJECTED CASH RUNWAY EXTENDED INTO 2026

* OCUPHIRE PHARMA INC - COMBINED COMPANY TO BE RENAMED OPUS GENETICS, TRADING AS 'IRD'

* OCUPHIRE PHARMA INC - GEORGE MAGRATH TO CONTINUE AS CEO OF COMBINED COMPANY

* OCUPHIRE PHARMA INC - STOCKHOLDERS TO OWN 58%, OPUS GENETICS STOCKHOLDERS 42% OF COMBINED CO

* OCUPHIRE PHARMA INC - LYNX-2 PHASE 3 TRIAL ON TRACK FOR TOP-LINE DATA IN Q1 2025

Source text for Eikon: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2477399954?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-23 05:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2477399954","market":"us","top_or_hot":-1,"title":"BRIEF-Ocuphire Pharma announces acquisition of Opus Genetics","media":"Reuters","content":"<html><body><p>Oct 22 (Reuters) - Ocuphire Pharma Inc   :</p><p>   * OCUPHIRE PHARMA ANNOUNCES ACQUISITION OF OPUS GENETICS</p><p>   * OCUPHIRE PHARMA INC - PROJECTED CASH RUNWAY EXTENDED INTO 2026</p><p>   * OCUPHIRE PHARMA INC - COMBINED COMPANY TO BE RENAMED OPUS GENETICS, TRADING AS 'IRD'</p><p>   * OCUPHIRE PHARMA INC - GEORGE MAGRATH TO CONTINUE AS CEO OF COMBINED COMPANY</p><p>   * OCUPHIRE PHARMA INC - STOCKHOLDERS TO OWN 58%, OPUS GENETICS STOCKHOLDERS 42% OF COMBINED CO</p><p>   * OCUPHIRE PHARMA INC - LYNX-2 PHASE 3 TRIAL ON TRACK FOR TOP-LINE DATA IN Q1 2025</p><p>Source text for Eikon:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Ocuphire Pharma announces acquisition of Opus Genetics</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Ocuphire Pharma announces acquisition of Opus Genetics\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-23 05:16 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Oct 22 (Reuters) - Ocuphire Pharma Inc   :   * OCUPHIRE PHARMA ANNOUNCES ACQUISITION OF OPUS GENETICS   * OCUPHIRE PHARMA INC - PROJECTED CASH RUNWAY EXTENDED INTO 2026   * OCUPHIRE PHARMA INC - ...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2477399954","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2477399954","pubTimestamp":1729631797,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"Oct 22  - Ocuphire Pharma Inc   :   * OCUPHIRE PHARMA ANNOUNCES ACQUISITION OF OPUS GENETICS   * OCUPHIRE PHARMA INC - PROJECTED CASH RUNWAY EXTENDED INTO 2026   * OCUPHIRE PHARMA INC - COMBINED COMPANY TO BE RENAMED OPUS GENETICS, TRADING AS 'IRD'   * OCUPHIRE PHARMA INC - GEORGE MAGRATH TO CONTINUE AS CEO OF COMBINED COMPANY   * OCUPHIRE PHARMA INC - STOCKHOLDERS TO OWN 58%, OPUS GENETICS STOCKHOLDERS 42% OF COMBINED CO   * OCUPHIRE PHARMA INC - LYNX-2 PHASE 3 TRIAL ON TRACK FOR TOP-LINE DATA IN Q1 2025Source text for Eikon:    Further company coverage:    ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药"},"translate_title":"简介-Ocuphire Pharma宣布收购Opus Genetics","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OCUP":0.9},"content_text":"Oct 22 (Reuters) - Ocuphire Pharma Inc   :   * OCUPHIRE PHARMA ANNOUNCES ACQUISITION OF OPUS GENETICS   * OCUPHIRE PHARMA INC - PROJECTED CASH RUNWAY EXTENDED INTO 2026   * OCUPHIRE PHARMA INC - COMBINED COMPANY TO BE RENAMED OPUS GENETICS, TRADING AS 'IRD'   * OCUPHIRE PHARMA INC - GEORGE MAGRATH TO CONTINUE AS CEO OF COMBINED COMPANY   * OCUPHIRE PHARMA INC - STOCKHOLDERS TO OWN 58%, OPUS GENETICS STOCKHOLDERS 42% OF COMBINED CO   * OCUPHIRE PHARMA INC - LYNX-2 PHASE 3 TRIAL ON TRACK FOR TOP-LINE DATA IN Q1 2025Source text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2477399954"}